FIELD: medicine.
SUBSTANCE: present invention relates to immunology. Disclosed are an isolated nucleic acid molecule encoding an anti-CD19 chimeric antigen receptor, an isolated anti-CD19 chimeric antigen receptor molecule, as well as a humanized anti-CD19-binding domain. Invention also discloses a vector, cells, a method for producing a cell, a method of producing a population of cells, a method for creating antitumour immunity and a method of treating. Described nucleic acid molecules encoding anti-CD19 CAR are also described.
EFFECT: present invention can find further application in therapy of various proliferative diseases associated with expression of CD19, particularly cancer.
83 cl, 12 dwg, 6 tbl, 6 ex
Title | Year | Author | Number |
---|---|---|---|
TREATING A MALIGNANT TUMOR USING A CHIMERIC ANTIGEN CD19 RECEPTOR | 2015 |
|
RU2718542C2 |
TREATMENT OF MALIGNANT TUMOR USING ANTI-CD19 ANTIGEN CHIMERIC RECEPTOR | 2015 |
|
RU2815417C2 |
CANCER TREATMENT WITH CHIMERIC CD33 ANTIGEN RECEPTOR | 2015 |
|
RU2747384C2 |
CANCER TREATMENT USING CHIMERIC ANTIGEN-SPECIFIC RECEPTOR BASED ON HUMANISED ANTI-EGFRvIII ANTIBODY | 2014 |
|
RU2708032C2 |
CHIMERIC ANTIGENIC (CAR) RECEPTOR AGAINST CD123 FOR USE IN TREATING MALIGNANT TUMORS | 2015 |
|
RU2724999C2 |
CHIMERIC ANTIGEN RECEPTORS FOR CANCER TREATMENT | 2017 |
|
RU2826270C2 |
TYPES OF COMBINATION THERAPY USING CHIMERIC ANTIGEN RECEPTORS AND PD-1 INHIBITORS | 2017 |
|
RU2809160C2 |
METHODS FOR PRODUCING CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR | 2015 |
|
RU2751362C2 |
CHIMERIC ANTIGEN RECEPTORS AND THEIR PRODUCTION METHODS | 2015 |
|
RU2753965C2 |
CD20 THERAPY, CD22 THERAPY AND COMBINATION THERAPY WITH CELLS EXPRESSING CHIMERIC ANTIGEN RECEPTOR (CAR) K CD19 | 2016 |
|
RU2752918C2 |
Authors
Dates
2020-01-23—Published
2014-03-15—Filed